Compare Icl Group Ltd (ICL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Illumina, Inc. — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.65B), while Illumina, Inc. trades at $192.36 (market cap $27.94B). The key difference: Illumina, Inc. is far larger — about 4.2× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.77% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ICL | ILMN | |
|---|---|---|
Market Cap | $6.65B | $27.94B |
Sector | Basic Materials | Health |
52-Week High | $7.03 | $194.33 |
52-Week Low | $4.80 | $91.00 |
Enterprise Value | $9.22B | $29.33B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.25, up 3.96% today, with neutral technical signals and mixed earnings history. The company maintains stable cash flow and recently completed an $800 million senior notes offering. Valuation metrics show a P/E of 24.05 and P/S of 0.88, while profitability margins remain modest. All four covering analysts rate the stock as Hold.
Outlook is cautious due to flat analyst sentiment and declining profit margins, though operational cash flow supports dividend payments. Key risks include raw material costs and foreign exchange volatility. The stock offers income via dividends but lacks near-term growth catalysts.
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
